Drugs such as insulin, which are related with APE1/Ref-1 reduction or the use of E3330, inhibiting APE1/Ref-1 redox function, would promote adipocyte differentiation or obesity, which should be considered in the new therapeutic target. The gene discussed is APEX1; the disease is obesity due to melanocortin 4 receptor deficiency.